/CDMO

CDMO Stock - Avid Bioservices, Inc.

Q: What is the analyst price target for CDMO?

Analyst price target information is not currently available for CDMO.

Q: What is CDMO's market cap?

Market capitalization information is not currently available for CDMO.

Healthcare|Biotechnology|NASDAQ

$12.49+0.00%

+$0.00 (+0.00%) • Feb 4

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-35.9%upside

Target: $8.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CDMO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.41

52W High$12.51

52W Low$5.90

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$139.91M	$149.27M	$119.60M	$95.87M	$59.70M
Gross Profit	$7.32M	$31.48M	$36.65M	$29.31M	$3.93M
Gross Margin	5.2%	21.1%	30.6%	30.6%	6.6%
Operating Income	$-18,678,000	$-2,607,000	$10.86M	$8.92M	$-10,585,000
Net Income	$-140,753,000	$560,000	$127.67M	$11.21M	$-7,256,000
Net Margin	-100.6%	0.4%	106.8%	11.7%	-12.2%
EPS	$-2.23	$0.01	$2.08	$0.06	$-0.13

Company Overview

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish0 Neutral/Bearish

Price Targets

$20

Average Target

↑ 60.1% Upside

Now

$20

Low

$20

Average

$20

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 28th 2023	William Blair	Initiation	Market Perform	-
March 14th 2023	KeyBanc Capital Markets	Upgrade	Overweight	$20

Earnings History & Surprises

CDMO

Beat Rate

35%

Last 20 quarters

Avg Surprise

-270.4%

EPS vs Estimate

Beats / Misses

7/13

Last 12 quarters

Latest EPS

$-0.22

Q4 2024

EPS Surprise History

Q1 24

-80.0%

$-0.09vs$-0.05

Q2 24

-71.4%

$-0.08vs$-0.05

Q3 24

-5085.2%

$-0.07vs$-0.00

Q3 24

-71.4%

$-0.07vs$-0.04

Q3 24

-63.7%

$-0.03vs$-0.02

Q3 24

-63.7%

$-0.03vs$-0.02

Q4 24

-83.3%

$-0.22vs$-0.12

Q4 24

-83.3%

$-0.22vs$-0.12

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Dec 10, 2024	$-0.12	$-0.22	-83.3%	✗ MISS
Q4 2024	Dec 10, 2024	$-0.12	$-0.22	-83.3%	✗ MISS
Q3 2024	Sep 9, 2024	$-0.02	$-0.03	-63.7%	✗ MISS
Q3 2024	Sep 9, 2024	$-0.02	$-0.03	-63.7%	✗ MISS
Q3 2024	Jul 2, 2024	$-0.04	$-0.07	-71.4%	✗ MISS
Q3 2024	Jul 2, 2024	$-0.00	$-0.07	-5085.2%	✗ MISS
Q2 2024	Apr 24, 2024	$-0.05	$-0.08	-71.4%	✗ MISS
Q1 2024	Mar 25, 2024	$-0.05	$-0.09	-80.0%	✗ MISS
Q4 2023	Dec 7, 2023	$-0.06	$-0.15	-150.0%	✗ MISS
Q3 2023	Sep 7, 2023	$-0.03	$-0.03	-9.1%	✗ MISS
Q2 2023	Jun 21, 2023	$-0.02	$0.05	+350.0%	✓ BEAT
Q1 2023	Mar 13, 2023	$0.03	$0.07	+128.5%	✓ BEAT
Q4 2022	Dec 6, 2022	$-0.00	$-0.01	-300.0%	✗ MISS
Q3 2022	Sep 6, 2022	$0.07	$0.04	-45.5%	✗ MISS
Q2 2022	Jun 29, 2022	$0.01	$0.07	+600.0%	✓ BEAT
Q1 2022	Mar 8, 2022	$0.05	$0.09	+80.0%	✓ BEAT
Q4 2021	Dec 7, 2021	$0.04	$0.10	+140.0%	✓ BEAT
Q3 2021	Sep 8, 2021	$0.04	$0.10	+166.7%	✓ BEAT
Q2 2021	Jun 29, 2021	$-0.00	$-0.04	-900.0%	✗ MISS
Q1 2021	Mar 8, 2021	$0.00	$0.01	+133.1%	✓ BEAT

Frequently Asked Questions about CDMO

What is CDMO's current stock price?

Avid Bioservices, Inc. (CDMO) is currently trading at $12.49 per share. The stock has moved +0.00% today.

What is the analyst price target for CDMO?

The average analyst price target for CDMO is $8.00, based on 1 analyst.

What sector is Avid Bioservices, Inc. in?

Avid Bioservices, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CDMO's market cap?

Avid Bioservices, Inc. has a market capitalization of $0.80 billion, making it a small-cap company.

Does CDMO pay dividends?

No, Avid Bioservices, Inc. does not currently pay a dividend to shareholders.